Poseida Therapeutics

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , Sept. 7, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company's Chief Financial Officer, Johanna Mylet, will present virtually at the H.C.

Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Poseida announced a collaboration agreement on Aug.3 focused on allogeneic CAR-T Program in hematologic cancers with Roche, potentially worth $6 billion; $110 million upfront, $110 million in near-term milestones; other collaboration benefits. This is Poseida's second major collaboration deal following Takeda collaboration agreement focused on gene therapy products announced in October 2021.

Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech

Announced strategic collaboration with Roche, with a $110 million upfront payment, to focus on the research and development of allogeneic CAR-T cell therapies directed to hematologic malignancies Completed an underwritten public offering adding multiple quality institutional shareholders with gross proceeds of $80.5 million Well capitalized with cash runway into at least mid-2024 SAN DIEGO , Aug. 11, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced business updates and financial results for the second quarter ended June 30, 2022. "We continue to advance our pipeline in both cell and gene therapy, powered by strategic collaborations that validate our unique genetic engineering platform technologies while giving us access to resources and non-dilutive capital," said Mark Gergen, Chief Executive Officer of Poseida.

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022

SAN DIEGO , Aug. 8, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the closing of its previously announced underwritten public offering of 23,000,000 shares of its common stock at a public offering price of $3.50 per share, including 3,000,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares. All of the shares were sold by Poseida.

Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO , Aug. 4, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.50 per share.  The gross proceeds to Poseida from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $70.0 million.

Poseida Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO , Aug. 4, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Poseida expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering.

Poseida Therapeutics Announces Proposed Public Offering of Common Stock

Poseida Therapeutics is developing P-BCMA-ALLO1 for multiple myeloma and P-MUC1C-ALLO1 for solid tumors; data readouts from both of these candidates are expected in the 2nd half of 2022. Poseida established a deal with Roche for allogeneic therapies targeting hematological malignancies; upfront payment of $110 million and potential to earn an aggregate of $6 billion in milestone payments.

Poseida Therapeutics: Even After Recent Partnership, Additional Upside Possible

Roche Holding AG

Source: Shutterstock Poseida Therapeutics (NASDAQ: PSTX ) stock is soaring on Wednesday after the clinical-stage biotechnology company announced a deal with Roche (OTCMKTS: RHHBY ). The agreement with Roche will have it working with Poseida Therapeutics to develop “allogeneic CAR-T therapies directed to hematologic malignancies.

Poseida Therapeutics (PSTX) Stock Rockets 79% on Roche Deal

Leveraging Poseida's novel approach to cell therapy and Roche's expertise in developing and commercializing therapies to transform cancer care, the collaboration is focused on advancing multiple existing and additional next generation allogeneic CAR-T programs directed to hematologic malignancies Poseida will receive $110 million upfront, could receive up to $110 million in near-term milestones and other payments, and is eligible for future development and commercial milestones and tiered royalty payments Poseida to host a brief conference call today at 8:30 a.m. ET SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced it has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies.

Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies

SAN DIEGO , July 26, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of geneticist George M. Church, Ph.D.

Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board

Publication highlights ability of Cas-CLOVER to perform multiplexed gene editing to produce allogeneic products with a high percentage of Tscm cells that may result in better tolerability and deeper clinical responses Cas-CLOVER has demonstrated lower off-target and translocation activity than other published technologies including CRISPR, TALENs and Base Editors SAN DIEGO , June 29, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced a peer-reviewed publication highlighting the potential of its proprietary Cas-CLOVER Site-specific Gene Editing System as a high-efficiency platform for the production of allogeneic CAR-T cells. The paper, titled " Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells ," was published online today in Molecular Therapy – Nucleic Acids.

Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products

SAN DIEGO , June 2, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that its virtual Annual Meeting of Stockholders (the "Annual Meeting") will be held on Thursday, June 16, 2022 at 1:00 p.m. PT. The Annual Meeting will be held through a live webcast.

Poseida Therapeutics Announces Virtual 2022 Annual Meeting of Stockholders

Preclinical data supports potential of P-ckit-ALLO1 as a less toxic preconditioning agent for hematopoietic stem cell (HSC) transplants P-ckit-ALLO1 eliminates >95% of hematopoietic stem and progenitor cells (HSPCs) and prolongs survival in mouse models of acute myeloid leukemia (AML) SAN DIEGO , May 17, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today will present preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 2022 Annual Meeting highlighting the use of anti-c-kit CAR-T cells as a preconditioning agent to enable hematopoietic stem cell (HSC) transplants. The ASGCT Annual Meeting is being held in Washington, D.C.

Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -60.34% and 42.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Misses Revenue Estimates

SAN DIEGO , May 12, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced updates and financial results for the first quarter ended March 31, 2022.  "2022 is shaping up to be an exciting year for the Company, as we work to demonstrate the differentiation of our CAR-T programs in the clinic and advance our wholly owned and partnered gene therapy programs towards IND-enabling studies," said Mark Gergen, Chief Executive Officer of Poseida.

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022

Preclinical data to be presented supports potential of anti-c-kit CAR-T cells as a highly specific and less toxic conditioning regimen for hematopoietic stem cell transplantation SAN DIEGO , May 2, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that preclinical data highlighting the use of anti-c-kit CAR-T cells, P-ckit-ALLO1 as a preconditioning agent to enable hematopoietic stem cell (HSC) transplants, will be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held in Washington, D.C. and virtually on May 16-19, 2022.

Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting

SAN DIEGO , April 28, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company's Chief Executive Officer, Mark Gergen, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 2:40pm PT in Las Vegas. A live webcast of the presentation will be available on the Investors & Media Section of Poseida's website, www.poseida.com.

Poseida Therapeutics to Present at BofA Securities 2022 Healthcare Conference

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 105.88% and 31.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates

SAN DIEGO, March 10, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced updates and financial results for the fourth quarter and full year ended December 31, 2021. "We continued to demonstrate strong progress on our key priorities in the fourth quarter even as the pandemic impacted all parts of our industry.

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021

SAN DIEGO, Feb. 23, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today beginning at 10:00am ET / 7:00am PT. Poseida Therapeutics hosts R&D Day focused on novel pipeline and technology innovations.

Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations

SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that Brent Warner has joined the Company as President, Gene Therapy effective February 21, 2022. "Brent brings deep pharmaceutical expertise and a strong track record of leadership in gene therapy and rare genetic diseases to Poseida, and I am excited to welcome him to our team," said Mark Gergen, Chief Executive Officer of Poseida.

Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy

SAN DIEGO, Feb. 17, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced interim results from its Phase 1 clinical trial of P-PSMA-101, the Company's solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer (mCRPC). These data are being presented today at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in a poster presentation entitled, "Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium

SAN DIEGO, Feb. 9, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will host a virtual R&D Day at 10:00 am - 1:30 pm ET / 7:00 - 10:30 am PT on Wednesday, February 23, 2022. Poseida to host second annual Virtual R&D Day on February 23, 2022.

Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Eric Ostertag as Executive Chairman and the transition of current President and Chief Business Officer, Mark Gergen, to the role of Chief Executive Officer effective as of February 1, 2022. The Company also provided a summary business update and 2022 preview.

Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen

SAN DIEGO, Dec. 20, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-MUC1C-ALLO1, the Company's allogeneic CAR-T product candidate targeting multiple solid tumor indications.  Poseida announces FDA clearance of IND for P-MUC1C-ALLO1, a fully #allogeneic CAR-T targeting multiple solid tumors.

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors

News for Poseida Therapeutics Stock (PSTX)